# Pizarra — PT-pseudo_4b950525e6a8 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_4b950525e6a8
Task: 1

Encounter: Urology - outpatient on 01 Mar 2025.
Referrer: Dr. F. de Boer (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 65-year-old male
  - PSA: 19.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.37 ng/mL²
  - PSA velocity: 2.0 ng/mL/yr
  - Prior PSA: 18.4 ng/mL
  - Prostate volume: 51.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.88825184 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypertension, Benign prostatic hyperplasia
  - Current medication: amlodipine, valsartan, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 19 ng/mL. PI-RADS 5. PSAD 0.37. Prostate volume 51 mL. csPCa 0.89.

Vitals: weight 80 kg, height 175 cm, BMI 26.1, BP 134/81 mmHg, HR 80 bpm. Smoking: Ex-smoker (30 pack-yr, quit 2022).

Chief complaint: Current PSA reading of 19.0 ng/mL alongside a previous prostate cancer diagnosis necessitates clinical review.

History: A 65-year-old retired shopkeeper, widowed, occupies a ground-floor flat shared with his partner, who helps manage daily routines. Alcohol consumption is entirely avoided, and he walks for twenty minutes daily to stay active. Lower urinary tract complaints are moderately bothersome, scoring 22 out of 35 on the IPSS, currently controlled with tamsulosin while amlodipine and valsartan address his hypertension. He carries a benign prostatic hyperplasia diagnosis. Smoking ceased in 2022 after accumulating 30 pack-years. His adult daughter serves as his main contact; she recently visited for a routine dermatology check on stable actinic keratosis. He reports no unexplained weight loss, bone discomfort, or haematuria.

Physical examination: DRE — texture: smooth and firm; symmetry: uniform; nodularity: absent. The prostate presents as symmetrically enlarged without palpable irregularities. Systemic review shows normal heart and lung sounds, with no hepatosplenomegaly or peripheral lymphadenopathy. Cardiovascular and respiratory systems remain unremarkable. Blood pressure registers at 134/81 mmHg, heart rate at 80 bpm, and vital parameters are stable.

Patient info: retired shopkeeper; Widowed; Lives in ground-floor apartment with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Walking 20 min/day; IPSS score: 22/35 (severe LUTS).

Recent other appointments: Dermatology — actinic keratosis check.
Admin: Patient self-employed; flexible appointment slots requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.44 +/- 0.15   (95% CI 0.14-0.73)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.15  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.99 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size/zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value?
  - previous_notes (get_previous_notes) -> What is the prior grade, surveillance pathway, and management agreement?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with current findings (PSA 19.0, PI-RADS 5), warrants a re-biopsy or deferral, as the initial panel was insufficient. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the specific clinical context of the PI-RADS 5 score in conjunction with the high PSA (19.0 ng/mL) and the prior positive biopsy status.
The prior did not account for the specific risk stratification provided by the guideline search, such as the risk matrix linking PI-RADS 5 and PSA density (0.37 ng/mL²) to cancer probability.
The prior did not consider the implication of the prior positive biopsy status in the context of the current high-risk findings.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.44 +/- 0.15, which falls into the 'discuss' tier, meaning the model cannot distinguish between the two outcomes.
The guideline search indicates that PI-RADS 5 lesions are associated with an 83% detection rate of csPCa, which contradicts a conservative approach suggested by the prior.
The prior failed to account for the potential for the current high PSA and PI-RADS 5 to override the prior positive biopsy status, which the protocol expert noted is the key missing piece.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trend beyond the headline value?
previous_notes - What is the prior grade, surveillance pathway, and management agreement?
previous_notes - Specifically, what is the documented prior grade from the previous biopsy?

GUIDELINE ANCHOR
The guideline search constrains the decision by linking PI-RADS scores to the likelihood of csPCa detection, noting that PI-RADS 5 lesions have an 83% detection rate of csPCa.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Radiology Division | Antoni van Leeuwenhoek | 15 February 2025
PI-RADS 5 lesion in the left peripheral zone (base/mid), measuring ~18 mm.
Prostate volume 51.0 mL; PSA density 0.37 ng/mL/mL.
csPCa predicted probability 0.88825184.

get_psa_trend
PSA trend shows a rise from 2.1 ng/mL (Jul 2023) to 6.3 ng/mL (May 2024) to 19.0 ng/mL (Mar 2025).

get_previous_notes
04 Jul 2024: Transrectal biopsy conducted, yielding a diagnosis of Gleason 4+4 carcinoma.

NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not explicitly require them, and the retrieved documents provided sufficient information regarding the biopsy status, imaging findings, and PSA trajectory.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- PI-RADS 5 lesion in the left peripheral zone (base/mid), measuring ~18 mm.
- PSA trend shows a significant rise, culminating at 19.0 ng/mL.
- Prior biopsy yielded a Gleason 4+4 carcinoma.

AGAINST sampling this patient now:
- Prior biopsy yielded a Gleason 4+4 carcinoma (implying prior diagnosis is established).

WHERE THIS LEANS
The evidence strongly suggests that the high-risk imaging (PI-RADS 5) combined with a significant PSA velocity and a prior confirmed cancer warrants further investigation, leaning towards biopsy.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

REOPENING THE BLACKBOARD (round 2 of 2).

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence, showing a PI-RADS 5 lesion, a significant PSA rise to 19.0 ng/mL, and a prior Gleason 4+4 diagnosis, strongly supports a recommendation for biopsy.

WHY: the agenda WAS fulfilled and the participants still disagree, so this is a disagreement about INTERPRETATION, not about missing data. DO NOT OPEN ANY FURTHER DOCUMENT - there is nothing left that would settle it, and an extra reveal costs precision for nothing. Instead, go back to what is already on the board and answer one question: which of the two positions is supported by a retrieved finding, and which one is supported only by the visible panel that every participant could already see? Name that finding.

---

# Ronda 2

## [9] GAPS AND DOUBTS (round 2)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the specific clinical context of the PI-RADS 5 score in conjunction with the high PSA (19.0 ng/mL) and the prior positive biopsy status.
The prior did not account for the specific risk stratification provided by the guideline search, such as the risk matrix linking PI-RADS 5 and PSA density (0.37 ng/mL²) to cancer probability.
The prior did not consider the implication of the prior positive biopsy status in the context of the current high-risk findings.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.44 +/- 0.15, which falls into the 'discuss' tier, meaning the model cannot distinguish between the two outcomes.
The guideline search indicates that PI-RADS 5 lesions are associated with an 83% detection rate of csPCa, which contradicts a conservative approach suggested by the prior.
The prior failed to account for the potential for the current high PSA and PI-RADS 5 to override the prior positive biopsy status, which the protocol expert noted is the key missing piece.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trend beyond the headline value?
previous_notes - What is the prior grade, surveillance pathway, and management agreement?
previous_notes - Specifically, what is the documented prior grade from the previous biopsy?

GUIDELINE ANCHOR
The guideline search constrains the decision by linking PI-RADS scores to the likelihood of csPCa detection, noting that PI-RADS 5 lesions have an 83% detection rate of csPCa.

## [10] EVIDENCE REPORT (round 2)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Radiology Division | Antoni van Leeuwenhoek | 15 February 2025
PI-RADS 5 lesion in the left peripheral zone (base/mid), measuring ~18 mm.
Prostate volume 51.0 mL; PSA density 0.37 ng/mL/mL.
csPCa predicted probability 0.88825184.

get_psa_trend
PSA trend shows a rise from 2.1 ng/mL (Jul 2023) to 6.3 ng/mL (May 2024) to 19.0 ng/mL (Mar 2025).

get_previous_notes
04 Jul 2024: Transrectal biopsy conducted, yielding a diagnosis of Gleason 4+4 carcinoma.

NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not explicitly require them, and the retrieved documents provided sufficient information regarding the biopsy status, imaging findings, and PSA trajectory.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- PI-RADS 5 lesion in the left peripheral zone (base/mid), measuring ~18 mm.
- PSA trend shows a significant rise, culminating at 19.0 ng/mL.
- Prior biopsy yielded a Gleason 4+4 carcinoma.

AGAINST sampling this patient now:
- Prior biopsy yielded a Gleason 4+4 carcinoma (implying prior diagnosis is established).

WHERE THIS LEANS
The evidence strongly suggests that the high-risk imaging (PI-RADS 5) combined with a significant PSA velocity and a prior confirmed cancer warrants further investigation, leaning towards biopsy.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [11] CLOSING CHECK (round 2)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The agenda was fully fulfilled by retrieving the MRI report, PSA trend, and previous notes. The evidence strongly leans towards biopsy due to the combination of PI-RADS 5, rising PSA, and prior confirmed cancer, despite the statistical prior suggesting no biopsy. The disagreement is about the interpretation of this combined evidence.

The chair decides on the record as it stands.

## [12] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

The conference reached a split between deferral and biopsy, with the statistical prior suggesting no biopsy and the evidence leaning towards it. The evidence supporting biopsy was driven by the combination of the PI-RADS 5 finding and the significant PSA rise to 19.0 ng/mL, which overturned the statistical prior's suggestion to defer. The guideline criterion abstained because the retrieved documents did not provide a definitive answer, leaving the decision to be based on the combined weight of the retrieved clinical findings.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
